

Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

Policy Number: CS2026D0108O
Effective Date: April 1, 2026

[Instructions for Use](#)

Table of Contents	Page
Application	1
Coverage Rationale	1
Applicable Codes	4
Background	4
Clinical Evidence	7
U.S. Food and Drug Administration	9
References	9
Policy History/Revision Information	12
Instructions for Use	12

Commercial Policy
None

Application

This Medical Benefit Drug Policy does not apply to the states listed below; refer to the state-specific policy/guideline, if noted:

State	Policy/Guideline
Arizona	Refer to the state’s Medicaid clinical policy
Florida	Refer to the state’s Medicaid clinical policy
Indiana	Refer to the state’s Medicaid clinical policy
Kansas	Refer to the state’s Medicaid clinical policy
North Carolina	None
Ohio	Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease (for Ohio Only)
Pennsylvania	Refer to the state’s Medicaid clinical policy
Texas	Refer to drug-specific criteria found within the Texas Medicaid Provider Procedures Manual

Coverage Rationale

This policy refers to the following drug products:

- Kisunla™ (donanemab-azbt)
- Leqembi® (lecanemab-imb)

Kisunla (donanemab-azbt) is medically necessary for the treatment of Alzheimer’s disease (AD) when all of the following criteria are met:

- For **initial therapy**, all of the following:
 - Diagnosis of **one** of the following based on National Institute on Aging and the Alzheimer’s Association (NIA-AA) criteria:
 - Mild cognitive impairment (MCI) due to Alzheimer’s disease; **or**
 - Mild dementia due to Alzheimer’s disease
 - and**
 - Submission of medical records (e.g., chart notes, laboratory values) documenting **one** of the following:

- Mini-Mental State Examination (MMSE) score of 20 to 30; **or**
- Montreal Cognitive Assessment (MoCA) score of 17 to 30; **or**
- Saint Louis University Mental Status (SLUMS) score of 17 to 30

and

- Submission of medical records (e.g., chart notes, laboratory values) documenting the presence of amyloid beta pathology, as evidenced by positive amyloid positron emission tomography (PET) brain imaging; **and**
- Other differential diagnoses [e.g., dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), vascular dementia, pseudodementia due to mood disorder, vitamin B12 deficiency, encephalopathy, etc.] have been ruled out; **and**
- **One** of the following:
 - Patient is not currently taking an anticoagulant (e.g., warfarin, dabigatran); **or**
 - **Both** of the following:
 - Patient is currently taking an anticoagulant (e.g., warfarin, dabigatran); **and**
 - Counseling has been provided that the combined use of Kisunla with anti-coagulant drugs may increase the risk of cerebral macrohemorrhage and prescriber attests that the patient has shared in decision-making to initiate Kisunla therapy

and

- Patient has no history of intracerebral hemorrhage within the previous year prior to initiating treatment; **and**
- Counseling has been provided on the risk of amyloid-related imaging abnormalities [ARIA characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin (ARIA-H)] and patient is aware to monitor for headache, dizziness, visual disturbances, nausea, and vomiting; **and**
- **All** of the following:
 - Counseling has been provided on how testing for apolipoprotein E (ApoE) epsilon 4 (ϵ 4) status informs the risk of developing ARIA when deciding to initiate treatment with Kisunla; **and**
 - Testing for ApoE ϵ 4 status has been offered to the patient and prescriber attests that the patient has shared in decision-making to initiate Kisunla therapy

and

- A baseline brain magnetic resonance imaging (MRI) has been completed within 12 months prior to initiating treatment; **and**
 - Not used in combination with other A β monoclonal antibodies (mAbs) for Alzheimer's disease (e.g., Leqembi)
- and**
- Prescribed by a neurologist, geriatric psychiatrist, or geriatrician who specializes in treating dementia; **and**
 - Kisunla dosing is in accordance with the United States Food and Drug Administration approved labeling; **and**
 - Initial authorization will be for no more than 12 months

- For **continuation of therapy**, **all** of the following:

- **One** of the following:
 - **Both** of the following:
 - Patient has received Kisunla therapy for less than or equal to 18 months; **and**
 - **One** of the following:
 - Post-treatment amyloid PET brain imaging is positive for amyloid based on visual read; **or**
 - Prescriber attests that amyloid PET imaging will be performed prior to 18 months of total treatment to assess for the effect of Kisunla treatment on amyloid plaque

or

- **Both** of the following:
 - Patient has received Kisunla therapy for greater than 18 months; **and**
 - Post-treatment amyloid PET brain imaging is performed at least once per 12 months and is positive for amyloid based on visual read

and

- **Both** of the following:
 - Submission of medical records (e.g., chart notes) confirming follow-up brain magnetic resonance imaging (MRI) has been completed after the initiation of therapy; **and**
 - **One** of the following:
 - ARIA has not been observed on MRI; **or**
 - All of the following:
 - ARIA has been observed on MRI; **and**
 - Prescriber attests that continuation of therapy with Kisunla is appropriate based on the severity of the patient's clinical symptoms; **and**
 - **One** of the following:
 - Follow-up MRI demonstrates radiographic resolution and/or stabilization; **or**

- Prescriber attests that continuation of therapy with Kisunla is appropriate based on the radiographic severity of ARIA

and

- Not used in combination with other A β monoclonal antibodies (mAbs) for Alzheimer's disease (e.g., Leqembi)
- and**
- Prescribed by a neurologist, geriatric psychiatrist, or geriatrician who specializes in treating dementia; **and**
 - Kisunla dosing is in accordance with the United States Food and Drug Administration approved labeling; **and**
 - Reauthorization is for no more than 12 months

Kisunla (donanemab-azbt) is unproven and not medically necessary for any indication other than Alzheimer's disease.

Leqembi (lecanemab-irmb) is medically necessary for the treatment of Alzheimer's disease (AD) when all of the following criteria are met:

- For **initial therapy**, **all** of the following:
 - Diagnosis of **one** of the following based on National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria:
 - Mild cognitive impairment (MCI) due to Alzheimer's disease; **or**
 - Mild dementia due to Alzheimer's disease

and

 - Submission of medical records (e.g., chart notes, laboratory values) documenting **one** of the following:
 - Mini-Mental State Examination (MMSE) score of 20 to 30; **or**
 - Montreal Cognitive Assessment (MoCA) score of 17 to 30; **or**
 - Saint Louis University Mental Status (SLUMS) score of 17 to 30

and

 - Submission of medical records (e.g., chart notes, laboratory values) documenting the presence of amyloid beta pathology, as evidenced by **one** of the following:
 - Positive amyloid positron emission tomography (PET) brain imaging; **or**
 - Cerebrospinal fluid (CSF) biomarker testing documents abnormalities suggestive of beta-amyloid accumulation in the brain (e.g., A β 42/40 ratio, p-tau 181/A β 42 ratio, t-tau/A β 42 ratio)

and

 - Other differential diagnoses [e.g., dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), vascular dementia, pseudodementia due to mood disorder, vitamin B12 deficiency, encephalopathy, etc.] have been ruled out; **and**
 - **One** of the following:
 - Patient is not currently taking an anticoagulant (e.g., warfarin, dabigatran); **or**
 - **Both** of the following:
 - Patient is currently taking an anticoagulant (e.g., warfarin, dabigatran); **and**
 - Counseling has been provided that the combined use of Leqembi with anti-coagulant drugs may increase the risk of cerebral macrohemorrhage and prescriber attests that the patient has shared in decision-making to initiate Leqembi therapy

and

 - Patient has no history of intracerebral hemorrhage within the previous year prior to initiating treatment; **and**
 - Counseling has been provided on the risk of amyloid-related imaging abnormalities [ARIA characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin (ARIA-H)] and patient is aware to monitor for headache, dizziness, visual disturbances, nausea, and vomiting; **and**
 - **All** of the following:
 - Counseling has been provided on how testing for apolipoprotein E (ApoE) epsilon 4 (ϵ 4) status informs the risk of developing ARIA when deciding to initiate treatment with Leqembi; **and**
 - Testing for ApoE ϵ 4 status has been offered to the patient and prescriber attests that the patient has shared in decision-making to initiate Leqembi therapy

and

 - A baseline brain magnetic resonance imaging (MRI) has been completed within 12 months prior to initiating treatment; **and**
 - Not used in combination with other A β monoclonal antibodies (mAbs) for Alzheimer's disease (e.g., Kisunla); **and**
 - Prescribed by a neurologist, geriatric psychiatrist, or geriatrician who specializes in treating dementia; **and**
 - Leqembi dosing is in accordance with the United States Food and Drug Administration approved labeling; **and**
 - Initial authorization will be for no more than 12 months
- For **continuation of therapy**, **all** of the following:
 - **Both** of the following:

- Submission of medical records (e.g., chart notes) confirming follow-up brain magnetic resonance imaging (MRI) has been completed after the initiation of therapy; **and**
 - **One** of the following:
 - ARIA has not been observed on MRI; **or**
 - **All** of the following:
 - ARIA has been observed on MRI; **and**
 - Prescriber attests that continuation of therapy with Leqembi is appropriate based on the severity of the patient's clinical symptoms; **and**
 - **One** of the following:
 - Follow-up MRI demonstrates radiographic resolution and/or stabilization; **or**
 - Prescriber attests that continuation of therapy with Leqembi is appropriate based on the radiographic severity of ARIA
- and**
- Not used in combination with other A β monoclonal antibodies (mAbs) for Alzheimer's disease (e.g., Kisunla); **and**
 - Prescribed by a neurologist, geriatric psychiatrist, or geriatrician who specializes in treating dementia; **and**
 - Leqembi dosing is in accordance with the United States Food and Drug Administration approved labeling; **and**
 - Reauthorization is for no more than 12 months

Leqembi (lecanemab-irmb) is unproven and not medically necessary for any indication other than Alzheimer's disease.

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPCS Code	Description
J0174	Lecanemab-irmb, for intravenous injection, 1mg
J0175	Injection, donanemab-azbt, 2mg

Diagnosis Code	Description
G30.0	Alzheimer's disease with early onset
G30.1	Alzheimer's disease with late onset
G30.8	Other Alzheimer's disease
G30.9	Alzheimer's disease, unspecified

Background

Alzheimer's disease (AD) is the most common cause of dementia and accounts for an estimated 60% to 80% of cases.

AD is characterized by deposition of A β plaques and neurofibrillary tangles (comprised of abnormal tau protein) in the brain, accompanied by synaptic dysfunction and neurodegeneration. The deposition of A β (as amyloid plaques) generally begins decades before any symptoms of AD are observed. More specifically, A β deposition is followed sequentially by markers of neurodegeneration, accumulation of tau pathology, and brain volume loss. This pre-symptomatic phase of AD will precede the emergence of AD symptoms 10 to 20 years prior.

Tau is the microtubule associated protein (MAP) of a normal mature neuron. Tau is a phosphoprotein that promotes the assembly of tubulin into microtubules and stabilization of their structure. In AD (and certain other related neurodegenerative diseases, called tauopathies), tau protein is abnormally hyperphosphorylated and aggregated into bundles of filaments. In AD, this tau pathology is seen as intraneuronal neurofibrillary tangles of paired helical filaments sometimes admixed with straight filaments. Aggregates of abnormally hyperphosphorylated filaments are also seen in dystrophic neurites surrounding the A β plaque core, and in the neuropil as neuropil threads.

Abnormal A β may be detected directly via PET imaging using tracers or indirectly by measuring the levels of the long form of A β in the CSF. P-tau and t-tau can also be detected using CSF and are used as biomarkers to detect the emergence of AD in patients with MCI.

Age of AD onset:

- Typical AD: AD is characteristically a disease of older age. The incidence and prevalence of AD increase exponentially with age, essentially doubling in prevalence every 5 years after the age of 65 years.
- Early-onset AD: Early-onset AD is less common and occurs in patients < 65 years of age. These patients often present with symptoms somewhat atypical for this disease, such as language, visual, or mood-behavioral changes rather than predominant memory loss.
- Inherited forms of AD: These forms of AD are rare (< 1% of all AD cases) and routinely present before 65 years of age, frequently in the fifth decade or earlier. Inherited forms of AD typically exhibit an autosomal-dominant inheritance pattern related to mutations in genes that alter A β protein production or metabolism, including amyloid precursor protein (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2).
- AD associated with Down syndrome: Patients with Down syndrome have an additional gene dose of APP due to trisomy of chromosome 21 and inevitably develop AD pathology. Symptoms tend to emerge at an earlier age, i.e., 10 to 20 years earlier than the general population with AD.

Risk factors for AD:

- Aging is an important risk factor for dementia. AD affects 5% to 10% of people > 65 years of age, and 50% of those \geq 85 years of age.
- Nonmodifiable risk factors for AD include female gender, Black race, Hispanic ethnicity, and genetic factors such as presence of the APOE gene.
- Modifiable risk factors for all-cause dementia include hypertension, diabetes, diet, and limited cognitive, physical, and social activities.

While the genetic basis for early-onset AD is much better understood, the genetic basis of late-onset AD is considered far more complex, with susceptibility conferred by a variety of more common but less penetrant genetic factors likely interacting with environmental and epigenetic influences. To date, the most firmly established genetic risk factor for late-onset disease is APOE:

- The APOE gene is located on chromosome 19 and exists in 3 alleles: epsilon 2, 3, and 4. The APOE epsilon 4 (ϵ 4) allele has been confirmed to be an important risk factor for AD in many clinical trials.
- Factors that may influence the impact of APOE ϵ 4 on AD risk include female gender, African/African-American race (although there are conflicting data), vascular risk factors (e.g., smoking, diabetes, hypertension, and hypercholesterolemia), and modifier genes/environment.
- Genetic testing is available for the known causative genes in early-onset AD but has not been widely adopted, likely in part because of the current lack of highly effective preventive or therapeutic strategies.

The symptoms at early stage AD are less pronounced than in later stages of AD, and therefore require measures that are different from those used in later stages.

The Clinical Dementia Rating – Sum of Boxes (CDR-SB) is an integrated scale that assesses both daily function and cognitive effects and was shown to be sufficiently sensitive and specific to detect change over time in early symptomatic AD patients. The scale integrates assessments from 3 domains of cognition (memory, orientation, judgment/problem-solving) and 3 domains of function (community affairs, home/hobbies, personal care). CDR-SB scores range from 0-18, with higher scores indicating greater disease severity. A minimal clinically important difference in CDR-SB has not been clearly defined but has been estimated to be 1-2 points. A CDR-SB score ranging from 0.5-4.0 has been reported to correspond to a Global CDR (CDR-G) score of 0.5. A CDR-SB score ranging from 4.5-9.0 has been reported to correspond to a CDR-G score of 1.

CDR-SB Score	Disease Severity
0	Normal
0.5-4.0	Suggests questionable cognitive impairment to very mild dementia
0.5-2.5	Suggests questionable cognitive impairment
3.0-4.0	Suggests very mild dementia
4.5-9.0	Suggests mild dementia
9.5-15.5	Suggests moderate dementia

CDR-SB Score	Disease Severity
16.0-18.0	Suggests severe dementia

The Mini-Mental State Exam (MMSE) is a widely used performance-based test of global cognitive status. The MMSE is a measure of cognition that includes 11 tasks relating to topics of word recall, attention and calculation, language ability, and visuospatial function. The scale ranges from 0 to 30 with a lower score reflecting greater cognitive impairment. It has several known limitations impacting sensitivity to change, particularly in earlier disease stages: substantial ceiling effects, sensitivity to practice effects, scores are impacted by patients' educational achievement, and learning effects are observed. The minimal clinically important difference of the MMSE in AD is estimated to be 1-3 points, and in early AD to be 1-2 points.

MMSE Score	Disease Severity
25-30	Normal to questionable cognitive impairment
19-24	Suggests mild dementia
10-18	Suggests moderate dementia
0-9	Suggests severe dementia

The Alzheimer's Disease Assessment Scale – Cognitive Subscale (13-Item version) (ADAS-Cog13) comprises both cognitive tasks and clinical ratings of cognitive performance. The scale items capture word recall, ability to follow commands, the ability to correctly copy or draw an image, naming, the ability to interact with everyday objects, orientation, word recognition, memory, comprehension of spoken language, word-finding, and language ability, with a measure for delayed word recall, and concentration/distractibility. The total score ranges from 0 to 85 with an increase in score over time indicates increasing cognitive impairment. The minimal clinically important difference of the ADAS-COG 13 in early AD is estimated to be 3 points.

The Integrated Alzheimer's Disease Rating Scale (iADRS) is a linear combination of its two components: the ADAS-Cog13 and the Alzheimer's Disease Cooperative Study – Instrumental Activities of Daily Living scale (ADCS-iADL) (range: 0-59; lower scores indicating greater impairment; items: 6a and 7-23). Because worse outcomes are indicated by higher scores on the ADAS-Cog13 and lower scores on the ADCS-iADL, the ADAS-Cog13 score is multiplied by -1 when calculating the iADRS score, such that lower iADRS scores indicate greater impairment. iADRS scores range from 0 to 144. The minimal clinically important difference of the iADRS has been suggested to be 5 points for MCI due to AD and 9 points for AD with mild dementia.

The Montreal Cognitive Assessment (MoCA) is a widely used screening test specifically designed to detect more subtle cognitive deficits that characterize mild cognitive impairment. Like the MMSE, the MoCA is scored on a 30-point scale, with items that assess delayed word recall, visuospatial/executive function, language, attention/concentration, and orientation. Studies examining head-to-head performance of patients on the MMSE and MoCA have shown that the MoCA is more difficult; MoCA scores are consistently lower than those obtained on the MMSE. The MoCA appears to be more sensitive than the MMSE for detecting MCI, though perhaps slightly less specific. A minimum clinically important difference of the MoCA in AD has not been described.

Assessment Scale	Minimal Clinical Important Difference
Clinical Dementia Rating-Sum of Boxes (CDR-SB)	1-2 points
Mini-Mental State Exam (MMSE)	1-3 points
Alzheimer's Disease Assessment Scale – Cognitive Subscale (13-Item version) (ADAS-Cog13)	3 points

The National Institute on Aging and the Alzheimer's Association (NIA-AA) research framework committee created a numeric clinical staging scheme applicable for diagnosing those in the Alzheimer's continuum. The six-stage numeric clinical staging scheme was brought forward largely unchanged (table below) into an Alzheimer's Association 2024 revision of the 2018 framework.

Stage	Numeric Clinical Staging – Applicable Only to Individuals in the Alzheimer's Continuum
Stage 0 asymptomatic, deterministic gene	<ul style="list-style-type: none"> No evidence of clinical change. Biomarkers in normal range.

Stage	Numeric Clinical Staging – Applicable Only to Individuals in the Alzheimer’s Continuum
Stage 1 asymptomatic, biomarker evidence only	<ul style="list-style-type: none"> Performance within expected range on objective cognitive tests. No evidence of recent cognitive decline or new symptoms.
Stage 2 transitional decline: mild detectable change, but minimal impact on daily function	<ul style="list-style-type: none"> Normal performance within expected range on objective cognitive tests. Decline from previous level of cognitive or neurobehavioral function that represents a change from individual baseline within the past 1 to 3 years, and has been persistent for at least 6 months. May be documented by evidence of subtle decline on longitudinal cognitive testing, which may involve memory or other cognitive domains but performance still within normal range. May be documented through subjective report of cognitive decline. May be documented with recent-onset change in mood, anxiety, motivation not explained by life events. Remains fully independent with no or minimal functional impact on activities of daily living (ADLs).
Stage 3 cognitive impairment with early functional impact	<ul style="list-style-type: none"> Performance in the impaired/abnormal range on objective cognitive tests. Evidence of decline from baseline, documented by the individual’s report or by observer (e.g., study partner) report or by change on longitudinal cognitive testing or neurobehavioral assessments. Performs daily life activities independently, but cognitive difficulty may result in detectable functional impact on complex ADLs (i.e., may take more time or be less efficient but still can complete – either self-reported or corroborated by an observer).
Stage 4 dementia with mild functional impairment	<ul style="list-style-type: none"> Progressive cognitive and mild functional impairment on instrumental ADLs, with independence in basic ADLs.
Stage 5 dementia with moderate functional impairment	<ul style="list-style-type: none"> Progressive cognitive and moderate functional impairment on basic ADLs requiring assistance.
Stage 6 dementia with severe functional impairment	<ul style="list-style-type: none"> Progressive cognitive and functional impairment, and complete dependence for basic ADLs.

Leqembi (lecanemab-irmb) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease.

Kisunla (donanemab-azbt) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease. Donanemab-azbt reduces amyloid beta plaques.

Clinical Evidence

Multiple investigational anti-A β antibodies have been developed with the goal of either reducing production of A β or lowering levels of aggregated A β present in the brain, the latter of which has been the most pursued approach. Many of these investigational drugs have failed to demonstrate efficacy and/or safety. Some explanations for the failures of previous anti-A β antibodies include the following:

- Inclusion of patients in clinical trials without evidence of A β pathology
- Unknown or no target engagement prior to initiation of phase 3 study (i.e., poor selectivity of drug for neurotoxic A β)
- Lack of robust and sustained inhibition of soluble A β oligomers
- Use of subtherapeutic doses (possibly due to decreased brain penetration)

- Inclusion of patients at later stages of AD dementia, when significant irreversible neurodegeneration has already occurred

FDA approval for lecanemab was based on Study 201, an 18-month, phase 2b, double-blind, placebo controlled, multicenter, randomized control trial that evaluated the safety and efficacy of lecanemab. The study aimed to establish the effective dose 90% (ED90), defined as the simplest dose that achieves $\geq 90\%$ of the maximum treatment effect. The primary endpoint was Bayesian analysis of 12-month clinical change on the Alzheimer's Disease Composite Score (ADCOMS) for the ED90 dose, which required an 80% probability of $\geq 25\%$ clinical reduction in decline versus placebo. Study 201 enrolled 854 patients, who were treated with lecanemab (609/854) or placebo (245/854). Of the total number of patients randomized, 71.4% were ApoE $\epsilon 4$ carriers and 28.6% were ApoE $\epsilon 4$ non-carriers. During the study, the protocol was amended to no longer randomize ApoE $\epsilon 4$ carriers to the 10 mg/kg every two weeks dose arm. ApoE $\epsilon 4$ carriers who had been receiving lecanemab 10 mg/kg every two weeks for 6 months or less were discontinued from study drug. The primary analysis conducted at Month 12 of treatment indicated that the 10 mg/kg IV biweekly dose (the effective dose) had a 64% probability to be better than placebo by 25% on ADCOMS at 12 months, missing the prespecified 80% probability threshold for the primary outcome.

The results for the Bayesian analysis for reduction of clinical decline at 18 months vs. placebo for 10 mg/kg biweekly on ADCOMS (-27%, with 97.7% probability to be superior to placebo), CDR-SB (33%, with 96.4% probability to be superior to placebo), and ADASCog14 (56%, with a 98.8% probability to be superior to placebo) were similar to the results from the corresponding conventional analyses for clinical measures when comparing mean change from baseline and least squares (LS) mean data.

The CLARITY AD phase 3 study was conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating – Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of lecanemab in participants with EAD in the Extension Phase and whether the long-term effects of lecanemab as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase. CLARITY AD was an 18-month, multicenter, double-blind, phase 3 trial involving persons 50 to 90 years of age with early Alzheimer's disease (mild cognitive impairment or mild dementia due to Alzheimer's disease) with evidence of amyloid on positron-emission tomography (PET) or by cerebrospinal fluid testing. Participants were randomly assigned in a 1:1 ratio to receive intravenous lecanemab (10 mg per kilogram of body weight every 2 weeks) or placebo. The primary end point was the change from baseline at 18 months in the score on the Clinical Dementia Rating – Sum of Boxes (CDR-SB; range, 0 to 18, with higher scores indicating greater impairment). Key secondary end points were the change in amyloid burden on PET, the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; range, 0 to 90; higher scores indicate greater impairment), the Alzheimer's Disease Composite Score (ADCOMS; range, 0 to 1.97; higher scores indicate greater impairment), and the score on the Alzheimer's Disease Cooperative Study – Activities of Daily Living Scale for Mild Cognitive Impairment (ADCSMCI-ADL; range, 0 to 53; lower scores indicate greater impairment). A total of 1,795 participants were enrolled, with 898 assigned to receive lecanemab and 897 to receive placebo. The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo [difference, -0.45; 95% confidence interval (CI), -0.67 to -0.23; $p < 0.001$]. Furthermore, a slope analysis demonstrated that lecanemab took 5.5 to 6 months more time to achieve the same CDR-SB as placebo at 18 months, indicating a 5.5 to 6 month slowing of progression. A β plaque reduction was a secondary endpoint and was studied in a subset of patients ($n = 698$). The adjusted mean change from baseline at 18 months was -55.48 centiloids in the lecanemab group vs. 3.64 centiloids in the placebo group (adjusted mean difference, -59.12 centiloids; 95% CI, -62.64 to -55.60; $p < 0.001$). Lecanemab resulted in infusion-related reactions in 26.4% of the participants and amyloid-related imaging abnormalities with edema or effusions in 12.6%.

The incidence of ARIA-E with lecanemab was 12.5% vs. 1.7% with placebo (symptomatic ARIA-E: 2.8% vs. 0% with placebo). In a sub study involving 698 participants, there were greater reductions in brain amyloid burden with lecanemab than with placebo (difference, -59.1 centiloids; 95% CI, -62.6 to -55.6). Other mean differences between the two groups in the change from baseline favoring lecanemab were as follows: for the ADAS-cog14 score, -1.44 (95% CI, -2.27 to -0.61; $p < 0.001$); for the ADCOMS, -0.050 (95% CI, -0.074 to -0.027; $p < 0.001$); and for the ADCS-MCIADL score, 2.0 (95% CI, 1.2 to 2.8; $p < 0.001$).

FDA approval for donanemab was based on TRAILBLAZER-ALZ 2, a double-blind, placebo-controlled, parallel-group study (Study 1, NCT04437511) in patients with Alzheimer's disease (patients with confirmed presence of amyloid pathology and mild cognitive impairment or mild dementia stage of disease, consistent with Stage 3 and Stage 4 Alzheimer's disease). Patients were enrolled with a Mini-Mental State Examination (MMSE) score of ≥ 20 and ≤ 28 and had a progressive change in memory function for at least 6 months. Patients were included in the study based on visual

assessment of tau PET imaging with flortaucipir and standardized uptake value ratio (SUVR). Patients were enrolled with or without concomitant approved therapies (cholinesterase inhibitors and the N-methyl-D-aspartate antagonist memantine) for Alzheimer's disease. Patients could enroll in an optional, long-term extension. In TRAILBLAZER-ALZ 2, 1,736 patients were randomized 1:1 to receive 700 mg of donanemab every 4 weeks for the first 3 doses, and then 1,400 mg every 4 weeks (n = 860) or placebo (n = 876) for a total of up to 72 weeks. The treatment was switched to placebo based on amyloid PET levels measured at Week 24, Week 52, and Week 76. If the amyloid plaque level was < 11 Centiloids on a single PET scan or 11 to < 25 Centiloids on 2 consecutive PET scans, the patient was eligible to be switched to placebo. Additionally, dose adjustments were allowed for treatment-emergent ARIA or symptoms that then showed ARIA-E or ARIA-H on MRI. At baseline, mean age was 73 years, with a range of 59 to 86 years. Of the total number of patients randomized, 68% had low/medium tau level and 32% had high tau level; 71% were ApoE ε4 carriers and 29% were ApoE ε4 noncarriers. Fifty-seven percent of patients were female, 91% were White, 6% were Asian, 4% were Hispanic or Latino, and 2% were Black or African American. The primary efficacy endpoint was change in the integrated Alzheimer's Disease Rating Scale (iADRS) score from baseline to 76 weeks. The iADRS is a combination of two scores: the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog13) and the Alzheimer's Disease Cooperative Study – Instrumental Activities of Daily Living (ADCS-iADL) scale. The total score ranges from 0 to 144, with lower scores reflecting worse cognitive and functional performance. Other efficacy endpoints included Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB), ADAS-Cog13, and ADCS-iADL. There were two primary analysis populations based on tau PET imaging with flortaucipir: (1) low/medium tau level population (defined by visual assessment and SUVR of ≥ 1.10 and ≤ 1.46), and (2) combined population of low/medium plus high tau (defined by visual assessment and SUVR > 1.46) population. Patients treated with donanemab demonstrated a statistically significant reduction in clinical decline on iADRS compared to placebo at Week 76 in the combined population [difference, 2.92 (95% CI, 1.51-4.33); p < .001] and the low/medium tau population [difference, 3.25 (95% CI, 1.88-4.62); p < .001]. Patients treated with donanemab demonstrated a statistically significant reduction in clinical decline on CDR-SB compared to placebo at Week 76 in the combined population [difference, -0.7 (95% CI, -0.95 to -0.45); p < .001]. There were also statistically significant differences (p < 0.001) between treatment groups as measured by ADAS-Cog13 and ADCS-iADL at Week 76. Dosing was continued or stopped in response to observed effects on amyloid imaging. The percentages of patients eligible for switch to placebo based on amyloid PET levels at Week 24, Week 52, and Week 76 timepoints were 17%, 47%, and 69%, respectively. Amyloid PET values may increase after treatment with donanemab is stopped. There is no data beyond the 76-week duration of TRAILBLAZER-ALZ 2 to guide whether additional dosing with donanemab may be needed for longer-term clinical benefit.

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Leqembi (lecanemab-irmb) is indicated for the treatment of Alzheimer's disease. Treatment with Leqembi should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Kisunla (donanemab-azbt) is indicated for the treatment of Alzheimer's disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of the disease, the population in which treatment was initiated in the clinical trials.

References

1. 2025 Alzheimer's disease facts and figures. *Alzheimer's Dement.* 2025 Apr 29;21(4):e70235. doi: 10.1002/alz.70235. PMID: PMC12040760.
2. Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: a review. *JAMA.* 2019;322(16):1589-1599.
3. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathic assessment of Alzheimer's disease. *Alzheimer's Dement.* 2012;8(1):1-13.
4. Food and Drug Administration. Combined FDA and Applicant PCNS Drugs Advisory Committee Briefing Document. November 6, 2020. https://fda.report/media/143503/PCNS-20201106-CombinedFDABiogenBackgrounder_0.pdf. Accessed February 22, 2023.
5. Iqbal K, Liu F, Gong CX, et al. Tau in Alzheimer's Disease and related tauopathies. *Curr Alzheimer Res.* 2010;7(8): 656-664.

6. Wolk DA, Dickerson BC. Clinical features and diagnosis of Alzheimer disease. UpToDate Web site. Updated September 30, 2024. <http://www.uptodate.com>. Accessed August 7, 2025.
7. Keene CD, Montine TJ, DeKosky ST. Epidemiology, pathology, and pathogenesis of Alzheimer's disease. UpToDate Web site. Updated July 10, 2025. <http://www.uptodate.com>. Accessed August 7, 2025.
8. Sherva R, DeKosky ST. Genetics of Alzheimer disease. UpToDate Web site. Updated April 8, 2025. <http://www.uptodate.com>. Accessed August 7, 2025.
9. O'Bryant SE, Lacritz LH, Hall LH, et al. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the National Alzheimer's Coordinating Center database. *Arch Neurol*. 2010;67(6):746-749.
10. Press D, DeKosky ST. Cholinesterase inhibitors in the treatment of dementia. UpToDate Web site. Updated June 18, 2025. <http://www.uptodate.com>. Accessed August 7, 2025.
11. Atri A. The Alzheimer's disease clinical spectrum diagnosis and management. *Med Clin n Am*. 2019;103:263-293.
12. Tolar M, Abushakra S, Sabbagh M. The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis. *Alzheimer's Dement*. 2020;16(11):1553-1560.
13. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's Dement*. 2011;7(3):270-279.
14. O'Bryant SE, Waring SC, Cullum CM, et al. Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes Scores: A Texas Alzheimer's Research Consortium Study. *Arch Neurol*. 2008;65(8):1091-1095.
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12(3):189-198.
16. Hansson O, Seibyl J, Stomruda E, et al. CSF biomarkers of Alzheimer's disease concord with amyloid- β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. *Alzheimer's Dement*. 2018 November; 14(11): 1470-1481. Supplementary data related to this article can be found at: <https://doi.org/10.1016/j.jalz.2018.01.010>.
17. S.K. Herukka et al. Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. *Alzheimer's & Dementia* 13 (2017) 285-295. Supplementary data related to this article can be found at: <http://dx.doi.org/10.1016/j.jalz.2016.09.009>.
18. Alcolea D, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. *Annals of Clinical and Translational Neurology* 2019; 6(9): 1815-1824.
19. MayoCliniclabs.com: ADEVL – Clinical: Alzheimer Disease Evaluation, Spinal Fluid. <https://www.mayocliniclabs.com/test-catalog/Overview/607273>. Accessed August 7, 2025.
20. Jack CR Jr, Bennett DA, Blennow K, et al: NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's Dement*. 2018 Apr;14(4):535-562.
21. Lifke V, Kollmorgen G, Manuilova E, et al: Elecsys Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. *Clin Biochem*. 2019 Oct;72:30-38.
22. Willems EAJ, van Maurik IS, Tijms BM, et al: Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. *Alzheimer's Dement (Amst)*. 2018 Sep 12;10:563-572.
23. Hansson O, Seibyl J, Stomrud E et al: CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. *Alzheimer's Dement*. 2018 Nov;14(11):1470-1481.
24. Schindler SE, Gray JD, Gordon BA, et al: Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. *Alzheimer's Dement*. 2018 Nov;14(11):1460-1469.
25. Shaw LM, Arias J, Blennow K, et al: Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. *Alzheimer's Dement*. 2018; 14(11):1505-1521.
26. Hansson O, Batrla R, Brix B, et al. The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. *Alzheimer's Dement*. 2021;17(9):1575-1582. doi:10.1002/alz.12316.

27. Clifford R. Jack Jr., et al: NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's Dement.* 2018 April; 14(4): 535-562. Doi:10.1016/j.jalz.2018.02.018.
28. Andrews JS, et al: Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials. *Alzheimer's & Dementia: Translational Research & Clinical Interventions* 5 (2019) 354-363.
29. Schrag A, Schott JM; Alzheimer's Disease Neuroimaging Initiative. What is the clinically relevant change on the ADAS-Cog? *J Neurol Neurosurg Psychiatry.* 2012 Feb;83(2):171-3.
30. Mendez MF, DeKosky ST. Mental status scales to evaluate cognition. UpToDate Website. Updated February 27, 2025. <http://www.uptodate.com>. Accessed August 7, 2025.
31. Minoshima S, Drzezga AE, Barthel H, et al. SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. *J Nucl Med.* 2016 Aug;57(8):1316-22.
32. Leqembi [package insert]. Nutley, NJ: Eisai Inc.; January 2025.
33. Clinicaltrials.gov Web site. <https://clinicaltrials.gov/ct2/show/NCT03887455>. Accessed August 7, 2025.
34. Van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease (Clarity AD). *NEJM.* 2023; 388:9-21.
35. Food and Drug Administration. Medical Review. Combined FDA and Applicant PCNS Drugs Advisory Committee Briefing Document. January 5, 2022. [761269Orig1s000SumR.pdf \(fda.gov\)](https://www.fda.gov/oc/2022/01/05/761269Orig1s000SumR.pdf). Accessed February 22, 2023.
36. Clinicaltrials.gov Web site. <https://clinicaltrials.gov/ct2/show/NCT03367403>. Accessed August 7, 2025.
37. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in Early Alzheimer's Disease. *n Engl J Med.* 2021;384(18):1691-1704. doi:10.1056/NEJMoa2100708.
38. Clinicaltrials.gov Web site. <https://www.clinicaltrials.gov/ct2/show/NCT01767311>. Accessed August 7, 2025.
39. Clinicaltrials.gov Web site. <https://clinicaltrials.gov/study/NCT05108922>. Accessed August 13, 2025.
40. Clinicaltrials.gov Web site. <https://clinicaltrials.gov/study/NCT05508789>. Accessed August 13, 2025.
41. Kisunla [package insert]. Eli Lilly and Company. Indianapolis, IN. July 2024.
42. Clinicaltrials.gov Web site. <https://clinicaltrials.gov/study/NCT05738486>. Accessed August 13, 2025.
43. Clinicaltrials.gov Web site. <https://clinicaltrials.gov/study/NCT04640077>. Accessed August 13, 2025.
44. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA.* 2023;330(6):512-527. doi:10.1001/jama.2023.13239.
45. Lansdall CJ, McDougall F, Butler LM, Delmar P, Pross N, Qin S, McLeod L, Zhou X, Kerchner GA, Doody RS. Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease. *J Prev Alzheimer's Dis.* 2023;10(1):9-18. doi: 10.14283/jpad.2022.102. PMID: 36641605.
46. Cedarbaum JM, Jaros M, Hernandez C, Coley N, Andrieu S, Grundman M, Vellas B; Alzheimer's Disease Neuroimaging Initiative. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. *Alzheimer's Dement.* 2013 Feb;9(1 Suppl):S45-55. doi: 10.1016/j.jalz.2011.11.002. Epub 2012 Jun 1. PMID: 22658286.
47. Coley N, Andrieu S, Jaros M, Weiner M, Cedarbaum J, Vellas B. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials. *Alzheimer's Dement.* Nov 2011;7(6):602-610 e2. doi:10.1016/j.jalz.2011.01.005.
48. Wessels AM, Rentz DM, Case M, Lauzon S, Sims JR. Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates. *Alzheimer's Dement (n Y).* 2022 Jun 6;8(1):e12312. doi: 10.1002/trc2.12312. PMID: 35676941; PMCID: PMC9169866.
49. Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, Hansson O, Ho C, Jagust W, McDade E, Molinuevo JL, Okonkwo OC, Pani L, Rafii MS, Scheltens P, Siemers E, Snyder HM, Sperling R, Teunissen CE, Carrillo MC. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimer's Dement.* 2024 Jun 27. doi: 10.1002/alz.13859. Epub ahead of print. PMID: 38934362.
50. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. *J Prev Alzheimer's Dis.* 2023;10(3):362-377. doi:10.14283/jpad.2023.30.

51. Rabinovici GD, Knopman DS, Arbizu J, et al. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. *Alzheimer's Dement.* 2025;21(1):e14338. doi:10.1002/alz.14338.

Policy History/Revision Information

Date	Summary of Changes
04/01/2026	<p>Application Louisiana</p> <ul style="list-style-type: none"> Removed content/language pertaining to the state of Louisiana <p>Applicable Codes</p> <ul style="list-style-type: none"> Updated list of applicable HCPCS codes to reflect quarterly edits; revised description for J0174 <p>Supporting Information</p> <ul style="list-style-type: none"> Archived previous policy version CS2026D0108N

Instructions for Use

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.